Ascendis Pharma A/S (NASDAQ:ASND) vs. Kalaris Therapeutics (NASDAQ:KLRS) Head-To-Head Comparison

Kalaris Therapeutics (NASDAQ:KLRS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Kalaris Therapeutics and Ascendis Pharma A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1	1	4	1	2.71
Ascendis Pharma A/S	1	0	17	1	2.95

Kalaris Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 129.13%. Ascendis Pharma A/S has a consensus price target of $291.56, indicating a potential upside of 27.17%. Given Kalaris Therapeutics’ higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Ascendis Pharma A/S.

Risk and Volatility

Kalaris Therapeutics has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Profitability

This table compares Kalaris Therapeutics and Ascendis Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-73.11%	-43.56%
Ascendis Pharma A/S	-30.85%	N/A	-19.63%

Earnings & Valuation

This table compares Kalaris Therapeutics and Ascendis Pharma A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44 million	($4.21)	-1.45
Ascendis Pharma A/S	$814.57 million	17.56	-$258.00 million	($4.40)	-52.11

Kalaris Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 75.0% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Kalaris Therapeutics beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.

About Kalaris Therapeutics

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.